Resverlogix Corporation

Ewelina B Kulikowski

Henrik C Hansen

Dean E Gilham

Sylwia Wasiak

Christopher R A Halliday

Gregory Steven Wagner

Laura M Tsujikawa

Sarah C Attwell

Kevin G McLure

Laura Tsujikawa

Christopher Ra Halliday

Dean Gilham

The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.

Compositions and therapeutic methods for the treatment of complement-associated diseases

Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.

Anti-inflammatory agents

Growing community of inventors

Calgary, Canada

Ewelina B Kulikowski